Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of
mRNA-1273 Vaccine Recipients

doi:10.1093/cid/ciab465

Warning: The NCBI web site requires JavaScript to function. more...

Try out PMC Labs and tell us what you think. Learn More.

Clin Infect Dis. 2021 May 20 : ciab465.

Published online 2021 May 20. doi: 10.1093/cid/ciab465

PMCID: PMC8241425

PMID: 34015087

Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

Alana F Ogata,^1,^2,³ Chi-An Cheng,^1,^2,³ Michaël Desjardins,^3,^4,⁵ Yasmeen Senussi,¹ Amy C Sherman,^3,⁴ Megan Powell,⁴ Lewis Novack,⁴ Salena Von,⁴ Xiaofang Li,⁶ Lindsey R Baden,^3,^4,⁶ and David R Walt^1,^2,³

Alana F Ogata

¹Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

²Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA

³Harvard Medical School, Boston, MA, USA

Find articles by Alana F Ogata

Chi-An Cheng

¹Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

²Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA

³Harvard Medical School, Boston, MA, USA

Find articles by Chi-An Cheng

Michaël Desjardins

³Harvard Medical School, Boston, MA, USA

⁴Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA

⁵Division of Infectious Diseases, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

Find articles by Michaël Desjardins

Yasmeen Senussi

¹Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Yasmeen Senussi

Amy C Sherman

³Harvard Medical School, Boston, MA, USA

⁴Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Amy C Sherman

Megan Powell

⁴Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Megan Powell

Lewis Novack

⁴Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Lewis Novack

Salena Von

⁴Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Salena Von

Xiaofang Li

⁶Center for Clinical Investigation, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Xiaofang Li

Lindsey R Baden

³Harvard Medical School, Boston, MA, USA

⁴Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA

⁶Center for Clinical Investigation, Brigham and Women’s Hospital, Boston, MA, USA

Find articles by Lindsey R Baden

David R Walt

¹Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

²Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA

³Harvard Medical School, Boston, MA, USA

Find articles by David R Walt

Author information Article notes Copyright and License information Disclaimer

This article has been cited by other articles in PMC.

Associated Data

Supplementary Materials: ciab465_suppl_Supplementary_Materials.
ciab465_suppl_supplementary_materials.docx (187M)
GUID: 0693EE6F-ACCA-4F17-974B-BB4CF3DD08D6

Abstract

SARS-CoV-2 proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. 11 of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day one after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of IgG and IgA.

Keywords: COVID-19, mRNA vaccine, SARS-CoV-2 antigens, immune responses, spike